Cirrhotic cardiomyopathy (CCM) is a significant complication of cirrhosis, but its progression and underlying mechanisms ...
Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Myqorzo is a cardiac myosin ...
Background Aortic stenosis (AS) frequently coexists with heart failure (HF), but its prevalence, prognostic impact and ...
It's getting trendy, and here's how to make it easy.
Background Patients with severe aortic stenosis (AS) are at high risk of mortality, regardless of symptom status. Despite ...
A University of Houston pharmacology researcher and expert in cardiac development has identified a new cause of—and repair ...
Review clinical classifications, diagnostic procedures, and management strategies for cardiomyopathy and heart failure in this comprehensive overview.
Cardiac device therapy has significantly evolved since the introduction of the first implantable pacemaker and the subsequent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback